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Glycine-rich B-glycoprotein  (1),  or  GBG,  ~ is  a  heat-labile  6.2S  pseudoglobulin  of 
normal  human  serum.  It  was  first recognized  by  its  reaction  in  fresh  serum  during 
immunoelectrophoresis with antiserum to one of its fragments, a 4.2S protein, glycine- 
rich y-glycoprotein or GGG (2). It subsequently became clear that  this fragment was 
the same as 52-glycoprotein II, described earlier by Haupt and Heide  (3)  as a  native 
serum  protein.  Antiserum prepared  against  the parent  molecule, GBG, also revealed 
an a,>mobility fragment,  glycine-rich a-glycoprotein or GAG (1). 
During  studies  of  a  patient  with  type  I  essential  hypercatabolism  of  C3  (4),  in- 
creased susceptibility to infection with pyogenic bacteria, and defects of complement- 
mediated functions,  it was observed that  these functions could be restored by a  5-6S 
heat-labile B-pseudoglobulin fraction of normal serum  (5).  Since C1, C4, and  C2 were 
in  normal  concentrations  in  his  serum,  it was  recognized  that  his abnormalities  in- 
volved a pathway to C3 activation alternative to the classical mechanism. The proper- 
din system  is such  a  pathway  (6)  and was shown over a  decade ago to involve a  hy- 
drazine-sensitive  protein,  factor  A  (7),  and  a  heat-labile  protein,  factor  B  (8),  in 
addition  to properdin  itself  and  Mg  ~+.  The  concentration  of properdin  protein  was 
normal in the patient's serum, but the activity of the properdin system was neverthe- 
less low as judged both by zymosan assay  (6)  and  the lack of bactericidal activity for 
a  pmperdin-sensitive strain of Shigella (9). 
GBG was undetectable in the patient's serum, but an enzyme, GBGase, was found 
which rapidly cleaved added  GBG  (10,  11).  His serum lacked a  normal inhibitor for 
this enzyme; the inhibitor was a 6S heat-labile/~-pseudoglobulin. Other proteins miss- 
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ing from his serum included the C3b inactivator (12)  and a  5S heat-labile/~-pseudo- 
globulin capable of  forming a  9S  complex with a  7S  protein in cobra venom,  CoF, 
such that the complex inactivated C3  (13,  14). 
It is the purpose of  this report  to define  the relationship between  GBG  and 
properdin factor B  and to determine whether GBG  reacts directly with CoF to 
form  a  C3-inactivating complex.  The  genetic polymorphism  in  GBG  (15)  was 
used  toward  these ends.  In humans,  there are  two  common  alleles  designated 
Gb ~" and Gb s  (for the fast and  slow electrophoretic mobilities of  the GBG  gene 
products)  and  two  rare  alleles, Gb  F1 and  Gb  sl, which synthesize very fast  and 
very slow GBG. A  brief report of these studies has been presented (16). 
Materials and Methods 
Protein Purification.--GBG was prepared as described previously (1).  C3 was purified by 
the method of Nilsson and Mtiller-Eberhard (17).  CoF was isolated from the venom of the 
Indian hooded cobra  (Naja  naja)  by the procedure described  by Mtiller-Eberhard and co- 
workers (13). All preparations were free of contaminants as judged by immunoelectrophoresis, 
agarose gel electrophoresis, and polyacrylamide gel electrophoresis. 
Radioiodin~tlon.--Purified  proteins were  labeled  with  l~sI  by  the  iodine  monochloride 
method (18).  Specific  activities ranged  from 6  X  104 to 3  X  105 cpm/#g.  Radioisotope  not 
bound to protein was removed by exhaustive dialysis. The final dialysis was against 0.15 M 
Veronal-buffered saline at pH 7.4 containing 2 X  10  -3 M Mg  2+. 
pilectrophoresis.--Agarose gel electrophoresis was performed on either a standard apparatus 
(19) for short separations or a modified device (20) for prolonged electrophoresis. For most ex- 
periments, the electrophoresis and gel buffers consisted of 0.05 M  Veronal at pH 8.6 containing 
2 X  10  -3 M Mg  ~+. For immunoelectrophoresis (21), antibody troughs were cut in the agarose 
gel between the migration paths of adjacent samples, antiserum was added, and patterns were 
developed overnight. In experiments involving 1251-labeled  proteins, the agarose gels after 
electrophoresis were  fixed  in methanol:water :acetic acid (45:45:10), washed  in water, and 
dried. Autoradiography was then carried out on Kodak No-screen X-ray film. 
Polyacrylamide gel electrophoresis (22) was performed with 5.5% acrylamide in the same 
apparatus as that used for short agarose gel electrophoresis (19). Mg  2+ was added to all buffers 
to a concentration of 2  X  10  _3 M. For autoradiography, the acrylamide gel, after fixation of 
separated proteins and washing, was covered with hot liquid 1% agarose in distilled waer and 
dried to a thin film. 
Pevikon electrophoresis was carried out by the method of Mfiller-Eberhard (23) with 0.05 
M  Veronal buffer at pH 8.6 containing 2 X  10  _3 M  magnesium acetate. Separation was con- 
tinued for 72 h at 4°C at 400 V. The eluates from 1-cm segments of the block were concentrated 
15-fold. 
Factor B Assay.--The assay for factor B  in the properdin system was carried out as de- 
scribed previously (24). The assay depends on restoration of the ability of zymosan to inacti- 
vate C6 in serum depleted of factor B by heating at 50°C for 30 min (RB). 
GBG Quan~itation.--GBG  was measured by the electroimrnunoassay of Laurell  (25).  In 
some instances, peak heights were used without reference to standards (relative concentration). 
In other cases,  absolute concentrations were determined. 
Gel Filtration.--Gel  filtration was carried out on 2.5 X  100 cm columns of Sephadex G-200. 
Column and elution buffers were 0.15 M  Veronal-buffered saline at pH 7.4 with 2 X  10  --3 M 
Mg  2+. To assess the extent of binding of 125I-labeled  CoF by serum, the gel filtration elution 
patterns of labeled CoF in buffer and in serum were plotted so that the lighter half of the 426  RELATIONSHIP  OF  ~-GLYCOPROTEIN  TO  SERUM  FACTORS 
major (7S) peak coincided. The difference  between the heavier parts of the serum and buffer 
curves were then determined  by subtraction.  Plotting the difference  yielded a  normally dis- 
tributed 9S peak. The weight of this 9S peak divided by the weight of the buffer 7S peak gave 
the decimal ratio of bound to total (unbound) labeled CoF. 
Specific Precipitation.--Specific rabbit  antisera  to  GBG,  ('oF,  and  ceruloplasmin  were 
added to fresh normal human serum (1 ml antiserum:0.075 ml or 0.040 ml human serum) which 
had previously been incubated for 30 min at 37°C with labeled or unlabeled CoF or GBG. 
These mixtures were incubated at 37°C for 1 h and overnight at 4°C. 1 ml of goat antiserum to 
rabbit proteins (including immunoglobulins) was then added and the mixtures were further in- 
cubated for 1.5 h at 37°C and overnight at 4°C. Specific precipitates were separated by centrifu- 
gation and washed twice in cold 0.15 M  phosphate-buffered saline.  The precipitates and the 
supernatants  combined with their respective washes were counted  in a gamma scintillation 
counter. 
RESULTS 
The Relationship Between GBG and Factor B in the Properdin System.--(a) As 
shown  in  Fig.  1,  increasing  amounts  of  GBG  added  to  the  RB  resulted  in 
increasing  inactivation  of  C6  on  subsequent  incubation  with  zymosan.  It  is 
evident  that  the  two  fractions  from  the  same  chromatographic  run  produced 
similar  dose-response  curves.  This  was  consistent  with  behavior  of  GBG  as 
factor B. 
(b)  Sera  containing  different  variants  of  GBG  showed partial  resolution  of 
these  variants  after  prolonged  electrophoresis  in  Pevikon.  It  can  be  seen  in 
Fig.  2  that  there  was  a  good correlation  between  factor  B  activity and  GBG 
protein  concentration.  In  the  case  of  Gb  FF  serum,  there  was  some  anodal 
extension of factor B  activity beyond the GBG protein peak. 
(c)  It is evident from Table I  that the serum of the patient with type Iessen- 
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FIG. 1.  Factor B activity in two fractions from the final DEAE-Sephadex elution step in 
the purification of GBG. Fraction 128  (O) was from the early portion of the elution peak, 
whereas fraction 175-176  (O) was from the end portion. Both fractions were free of detectable 
contaminants.  GBG concentrations are expressed  as micrograms per milliliter in the final re- 
action mixtures. (o--o) 
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FIG.  2.  Factor  B  activity  (0)  and  GBG  concentration  (O)  in  fractions from  Pevikon 
electrophoresis of sera containing different genetic variants  of GBG.  The anode was at  the 
right in each instance. Gb types of the sera were: SS (upper left), F]S (upper right), FS1 (lower 
left), and FF (lower right). 
tial hypercatabolism of C3  lacked significant factor B  activity. After addition 
of GBG, factor B  activity was restored but was progressively lost during incu- 
bation with the patient's serum at 37°C for 30 min. As determined  by immuno- 
electrophoresis, the added GBG was completely cleaved by this time. 428  RELATIONSHIP  OF  fl-GLYCOPROTEIN  TO  SERUM  FACTORS 
TABI,E  [ 
Interaction qf Serum j)'om  lhe Patient wilh Type I  Es'senfial  tlypercatabolism of C3 with GBG 
RB  Buffer*  Patient's  Normal human  GBG +  Preincuba-  C6  inactivation  serum  serum  tion at 37°C  by zymosan 
ml  ml  ,zl  ml  m/  min  ~ 
0,1  0.1  -  4 
0,1  0.05  0.05  4 
0.1  0.05  0.05  15  48 
O. 1  0.05  -  O. 05  -  30  48 
0.1  0.05  -  0.05  60  45 
O. 1  0.05  -  0.05  56 
0.1  0.05  -  0 .(15  30  57 
0.1  0.05  0.05  60  56 
0.1  0.05  0.05  53 
0.1  0,05  0.03  15  9 
O. 1  0.05  0.05  30  --3 
* Veronal-buffered  saline, pH  7.4, ionic strength 0.15,  containing 1.5  X  10  -4  M  Ca  2-~ and 
5  X  10  -4  M  Mg  9"+ and  0.05%  gelatin  (Kind  and  Knox  Gelatin  Co.,  Camden,  N.  J.,  type 
21381. 
{ Final concentration 30 mg/100 ml in reaction mixtures. 
Does  GBG  Form  a  C3-1naclivating  Complex with CoF?--(a)  Fractions from 
prolonged electrophoresis in  Pevikon  of  sera containing  different variants  of 
GBG were tested for their ability to convert ~25I-labeled C3  in the presence of 
CoF  on  subsequent  incubation  at  37°C.  Fig.  3  shows  the  distribution of  C3 
inactivation in four such  sera.  In no  instance did this coincide in distribution 
with  GBG  protein,  nor  did it  show  evidence  of  the  bimodality of  the  GBG 
variants.  In  general,  the  mediation  of  C3  inactivation by  CoF  had  the  ap- 
proximate electrophoretic mobility of Gb $1 to S. 
(b)  Evidence for complex formation between GBG and CoF in whole serum 
was  sought  by  adding  CoF  to  sera  containing  the  rare  fast  and  slow  GBG 
variants  in  amounts  roughly  equimolar  to  GBG  concentration.  During  im- 
munoelectrophoresis, such sera produced clear-cut double arcs with anti-GBG 
(Fig. 4) but the precipitin arcs of CoF were single, the same as those produced 
by CoF in buffer,  and did not correspond in any way to the GBG arcs in  the 
same serum.  There  was no  conversion of GBG after the addition of CoF and 
incubation at 37°C for 30 rain. 
(c)  A  mixture of  [t~i]CoF and  unlabeled CoF in a  total  amount  equimolar 
to GBG content was added to normal serum and the mixture was incubated at 
370(  2 for 30  rain.  During  gel  filtration through  Sephadex  G-200,  as shown  in 
Fig. 5,  the [~:'I]CoF formed three peaks. That appearing with the void volume 
(19S) was probably aggregated material since it was also present in buffer alone. 
The  major  peak  (7S)  corresponded  to  uncomplexed  CoF.  The  middle  peak 
(9S)  represented  a  complex  with  a  human  serum  protein,  since  it  was  not ALPER~  GOODKOFSKY,  AND  LEPOW  429 
I:IG. 3.  GBG concentration and serum mediation of CoF inactivation of C3 in fractions 
from Pevikon electrophoresis of sera containing different genetic variants of GBG. The anode 
was at the right in each instance. Gb types of the sera were: SS (upper left), F1S (upper right), 
FS1 (lower left), and FF (lower right), rlhe distribution of the serum mediator of C3 inactiva- 
tion by CoF was assessed by incubating the electrophoretic fractions (in Mg  2+) with purified 
CoF and  1~5I-labeled C3 and subjecting the mixtures to agarose gel electrophoresis and auto- 
radiography. The autoradiographic patterns themselves are shown for Gb F1S. Native C3 is 
the slower band; inactivation is reflected by conversion to the more rapid band (C3i). For this 
and the remaining sera, C3 inactivation was graded on a scale of 1-4+, shown above each of 
the GBG distribution patterns. 
FIG. 4-.  Prolonged immunoelectrophoresis ila agarose gel. The anode was at the left. 430  RELA'I'IONSIIIP OF  fl-GLYCOPROTEIN TO  SERUM FACTORS 
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FIG. 5.  Gel filtration through Sephadex G-200 of serum incubated with [12aI]CoF and un- 
labeled CoF at a final CoF concentration of 50 mg/100  ml.  GBG concentrations were de- 
termined in all fractions.  The positions of the three major protein peaks of the serum  are 
indicated. 
demonstrable during gel filtration of CoF in buffer and comprised 4% of labeled 
CoF added. GBG was eluted as a single symmetrical 6S peak, identical with that 
observed during  gel filtration of fresh  serum  without  added  CoF.  The  possi- 
bility that  GBG  complexed with  CoF  might  be  antigenicalty "masked"  was 
ruled out  by  immunochemically quantitating  GBG  in  serum  to  which  either 
CoF or buffer was added. The concentration of GBG in the first instance was 
31 mg/100 ml and in the second it was 32.5 rag/100 ml. 
(d)  Labeled and unlabeled CoF were  added to normal  serum  samples to  a 
final concentration of  1 rag/100 ml  or 50 mg/100 ml. If CoF and  GBG in the 
serum formed a  complex, it should be possible to precipitate a  significant por- 
tion  of  the  labeled CoF  with  antiserum  to  GBG.  As  shown  in  Table  II,  at 
neither concentration of CoF was this the case. Antiserum to GBG precipitated 
the  same percentage of the  [msI]CoF  as did anticeruloplasmin. When  labeled 
GBG was added to serum and unlabeled CoF was added at either 1 or 50 mg/ 
100  ml, the results were similar (Table II) in that  labeled GBG was not pre- 
cipitated  by  antiserum  to  CoF,  although  the  percentage  label  precipitated 
at a  CoF concentration of 1 mg/100  ml was 2~  times that at 50 mg/100  ml. 
It may be, therefore, that the anti-GBG used contained antibody to the protein 
capable of binding to CoF. The much lower percentage precipitation of labeled 
CoF in serum at  1 mg/100  ml compared with the percentage at 50 mg/100 ml 
may be  explained by antigenic masking of CoF in  complex with  the binding 
protein. 
(e)  Although  most  preparations  of  GBG  when  incubated  with  CoF  and 
~2aI-labeled C3  in  the  presence  of  Mg  2+  did  not  result  in  C3  conversion  as ALPER,  GOODKOFSKY~  AND  LEPOW  431 
judged by agarose gel electrophoresis and autoradiography, they all had factor 
B  activity.  A  single preparation  did  induce  C3  conversion in  the presence  of 
CoF. This preparation  was studied for its interaction  with  CoF in polyacryla- 
mide gel electrophoresis. 
Fig.  6  shows  that  when  this  preparation  was  mixed  in  molar  excess  with 
labeled  CoF,  a  complete  slowing  of  the  electrophoretic  mobility  of  the  CoF 
TABLE  II 
Precipilation of ~%l-Labded CoF or GBG in Serum by Antisera to GBG, CoF, and Ceruloplasmin 
CoF* +  NHS  CoF -k NHS  CoF* -}- NHS  CoF +  NHS 
Antiserum to  (1 rag/100 ml)~:  (1 rag/100 ml)+  +  -k GBG*  (50 mg/100~ml) +  +  (50 +mg/100GBG*ml)~: 
%~  %~  %§  %~ 
GBG  2.0  73.6  0.9  82.4 
Ceruloplasmin  2.9  2.2  2.3  0.8 
CoF  23.5  5.6  89.0  1.6 
* Labeled with 125I. 
Concentrations in parentheses are final CoF concentrations in serum. 
§ Percent offered radioactivity  precipitated. 
FIG. 6.  Autoradiography  of polyacrylamide  gel electrophoresis of mixtures  of purified 
125I-labeled and unlabeled CoF and GBG. Labeled proteins are indicated by asterisks. 
occurred.  When,  on the other hand,  a  molar excess of CoF was added  to  this 
preparation of GBG labeled with 125I, most of the GBG remained  unaltered in 
electrophoretic mobility. A small portion of the radioactivity migrated with the 
mobility of complexed CoF. 
(f)  A  partially  purified  preparation  of  GBG,  free of GBGase  inhibitor  but 
containing the CoF-binding protein,  was incubated  in the patient's  serum fol 
30 rain at 37°C. This resulted in complete cleavage of the GBG and, as indicated 
earlier,  complete  destruction  of factor  B  activity.  When  12~I-labeled  C3  was 
added  to this  mixture  and  it was incubated for an  additional  30 rain at 37°C, 432  RELATIONSHIP  OF  fl-GLYCOPROTEIN  TO  SERUM  ~'ACTORS 
no  more  C3  conversion occurred  than  was  observed  in normal  serum  (Fig.  7). 
However, when CoF was added,  C3 conversion did occur. 
Estimates ~( the Concentration  in A'ormal Serum of the CoF-Binding Protein.-- 
(a)  The  previous  experiments  suggested  that  some preparations  of  GBG  were 
contaminated  with small  amounts  of protein  capable  of complexing with  CoF. 
To  determine  approximately  the  concentration  of this  CoF-binding protein  in 
normal  serum,  labeled  CoF  was added  to  two sera in varying final  concentra- 
tions from  25  mg/100  ml  to 0.5  rag/100  ml and  incubated  for 30 rain  at 37°C. 
The  mixtures  were  then  subjected  to  polyacrylamide  gel  electrophoresis  and 
autoradiography.  Fig. 8  shows  that  even at  a  CoF concentration  as low  as 0.5 
rag/100 m/some of the CoF remained in free form. If the complex is equimolar, 
as is suggested by the presence of only a single slowed band,  then the concentra- 
tion of CoF-binding protein was less than 0.5  rag/100 ml. 
FIG. 7.  Autoradiography of agarose gel electrophoresis of  (from  left to right):  (a)  1251- 
labeled C3 (C3") incubated with normal human serum for 30 min at 37°C ; (b) a partially l)uri- 
fled preparation of GBG containing the CoF-binding protein incubated at 37°C for 30 rain and 
then with ('3* in buffer for an additional 30 rain; (c) the same as the preceding except that CoF 
was added in the second incubation; (d) the same as b except that serum from the patient with 
type I  essential hypercatabolism of C3 was substituted for buffer (to supply  GBGase)  in  the 
first incubation; his serum contains no detectable CoF-binding protein;  (e)  the same as the 
preceding except that  Col" was  added  in  the second  incubation.  Note that  C3  conversion 
greater than in normal human serum alone occurs only in c and e (in the presence of CoF) in- 
dicating preservation of CoF-binding protein activity despite conversion of GBG. We have no 
explanation for the apparent  increase in Col; binding protein activity after incubation in the 
patient's serum. 
1:I<;. 8.  Autoradiography of polyacrylamide gel eleetrophoresis of mixtures of 125I labeled 
CoF with serum at different final concentrations of Col". The faster band represents free Col", 
the slower is CoF complexed  with a serum protein. ALPER~ G00DKOFSKY~ AND  LEPOW  433 
(b)  One interpretation of the experiment shown in Fig. 5 is that CoF added 
to a final serum concentration of 50 rag/100 ml (equimolar to the GBG content) 
is very much in  excess of the  binding  capacity of the  serum.  Thus,  the pre- 
ponderant  7S peak represented  uncomplexed  CoF and only  4%  of  CoF  was 
bound. To test this hypothesis, 125I-labeled CoF was added to normal serum to 
a concentration of 0.17 mg/100 ml, below the CoF-binding capacity estimated 
in the previous experiment. Fig. 9 shows that under these conditions all of the 
labeled  CoF shifted  to  the 9S  area during  gel filtration  and  the  7S peak was 
completely  absent.  Thus,  the  CoF-binding  capacity  of  normal  serum  was 
between 0.17 and 2 rag/100 ml or under 6.5 % of the concentration of GBG. 
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FIG. 9.  Gel filtration through Sephadex G-200 of serum incubated with [~aI]CoF at a 
final CoFconcentrationof0.17 mg/100 ml. Comparewith Fig. 5 and note the complete  shift of 
labeled CoF from the 7S to the 9S position. 
DISCUSSION 
Three  lines  of  evidence  have  been  presented  which  dearly  establish  that 
GBG is the previously described factor B in the properdin system. (a) Purified 
preparations of GBG restored the factor B  activity of serum heated  at  50°C 
for 30 rain. The observation that two fractions from different parts of the final 
elution peak of GBG from DEAE-Sephadex had similar factor B activities per 
microgram  of  protein  provides  additional  confirmation  of  this  identity.  (b) 
Factor B  activity paralleled GBG protein concentration in the electrophoreti- 
tally separated  genetic variants.  Since  specific genetic  variation occurs inde- 
pendently at the various loci  that determine the  structure  of individual  pro- 
teins,  if activity parallels  protein  distribution  for variants,  particularly  rare 
ones, then the activity must be a function of the molecule in question. This has 
recently been shown to occur in the case of genetic variants of C3, even for their 
minor gene-specific anodal  components (26).  (c)  GBGase in  the serum of the 434  RELATIONSHIP  OF  ~-GLYCOPRO'FI,;IN  TO  SERUM  FACTORS 
patient with type I essential hypercatabolism of C3 destroved factor B activity 
as it cleaved GBG. 
The anticomplementary activity of snake venom has been  a  subject  of in- 
vestigation throughout virtually the entire history of the study of complement 
itself. It was noted in  1894 that putrefaction occurred very rapidly in persons 
who died of snake bites and that their serum lacked the bactericidal activity of 
normal serum (27). Flexner and Noguchi in 1902 (28)  showed that the venoms 
of many snakes destroyed complement activity in vitro. Only two components 
of complement were known in  1912, when Ritz (29)  showed that the action of 
venom was on neither. This observation prompted him to define a  third com- 
ponent.  It was only much later when purification  techniques  were developed 
allowing  further  separation  of  this  third  component  that  the  specific  target 
protein  of venom  action  could  be  delineated.  This  was  identified  as  C3  (in 
modern terms) by Klein and Wellensieck (30). The attack was shown by Nelson 
(31)  to be indirect, involving a heat-labile serum protein. Miiller-Eberhard and 
co-workers (13,  14) further characterized the serum protein as a 5S  B-pseudo- 
globulin, demonstrated that a complex was formed between this protein and the 
venom factor (CoF) and showed that this complex bore C3-cleaving activity. 
Since the serum of the patient with type I  essential hypercatabolism of C3 
lacked the CoF-binding protein, the possibility that GBG was this protein was 
considered  earlier  (5).  However,  since  cobra venom  added  to  normal  serum 
failed to alter the  gel  filtration  characteristics of GBG, this seemed unlikely. 
The present studies provide considerable evidence that these two proteins are 
distinct.  (a) The distribution in electrophoretic fractions of the mediator of C3 
inactivation by CoF differed from that of GBG in sera containing GBG vari- 
ants. (b) The distribution of CoF in sera containing GBG variants in imnmno- 
electrophoresis  differed  completely  from  the  distribution  of  GBG.  (c)  No 
alteration in the size of GBG could be detected on gel filtration of serurn incu- 
bated with labeled CoF despite complex formation of the latter with a serum 
protein.  (d)  It was not possible to precipitate  CoF  added  to  serum  by anti- 
GBG, nor GBG by anti-CoF.  (e) Most preparations of GBG did not promote 
C3 conversion by CoF; the one preparation that did showed a small amount of 
contamination  with  a  CoF-binding  protein.  (f)  GBGase  cleaved  GBG  and 
destroyed factor B  but did not destroy' CoF-mediated conversion of C3.  The 
lack of CoF binding by factor B has also been observed by Hunsicker and his 
colleagues (32)  in whole serum and in partially purified form. 
It appears that the  CoF-binding protein is a  trace serum protein occurring 
at a concentration less than 6.5% of that of GBG. It is clear that GBG and the 
major protein  of the  C3 proactivator  (C3PA)  isolated by G6tze and Mftller- 
Eberhard (33)  are the same. The observations in this report make it likely that 
contamination of C3PA preparations bv traces of CoF-binding protein would 
not be detectable by standard  electrophoretic or immunoelectrophoretic tech- 
niques.  We previously reported  that  C3PA  preparations  had  the  activity of ALPER,  GOODKOFSKY,  AND  LEPOW  435 
factor B in the properdin system (24) and the present observations are entirely 
consistent with this finding. Similar dose-response relationships were observed 
while testing C3PA and GBG preparations for factor B activity. 
Despite the multiple serum protein deficiencies in  the patient with  type I 
essential hypercatabolism of C3  (4, 5,  10-12), the only protein thus far shown 
to be subject to proteolytic attack in his  serum in  GBG. This cleavage was 
found in the present study to be accompanied by loss of factor B activity. The 
identification of GBG with factor B  thus helps to clarify the patient's abnor- 
malities  in  activities  of  the  properdin  system  and  to  reemphasize  the  im- 
portance of the properdin system in the maintenance of host resistance to in- 
fection. 
Our experiments do not rule out the participation of GBG, its fragments, or 
other serum proteins in the attack of CoF-binding protein-CoF complex on C3 
or on later-acting complement components. Similarly, we have not yet identi- 
fied the mediator of the attack by GBG or one of its fragments on C3  (10). 
This mediator, apparently missing from the serum of the patient with type I 
essential hypercatabolism of C3, was not present in the partially purified prepa- 
ration containing GBG and CoF-binding protein. 
If, as seems to us to be the case, factor B  is distinct from the CoF-binding 
protein, the role of the latter in the properdin or alternate pathway to C3 in- 
activation remains to be defined. The present experiments do not rule out the 
possibility that the CoF-binding protein is related to and perhaps intimately 
involved in the properdin pathway. Indeed, this protein, as well as factor B, is 
undetectable in the serum of the patient with type I  essential hypercatabolism 
of C3. 
SUMMARY 
Factor B  activity of the properdin system was  found to be identical with 
purified glycine-rich 13-glycoprotein  (GBG) but was  distinct from the normal 
human  serum  protein  capable  of forming a  C3-inactivating  complex with  a 
protein from cobra venom  (CoF).  Factor B  activity coincided with  electro- 
phoretically separated GBG genetic variants, whereas the CoF-binding protein 
did not. GBGase destroyed factor B as it cleaved GBG but did not destroy the 
C3-inactivafing  activity of  the  CoF-binding  protein.  During  incubation  of 
serum with  CoF,  GBG did not change in molecular size,  nor was  there any 
coincidence in the immunoelectrophoretic mobilities of CoF and GBG. It was 
not possible to precipitate labeled CoF incubated with serum by anti-GBG, nor 
labeled GBG from serum incubated with CoF by anti-CoF. 
The CoF-binding capacity of serum was 2 rag/100 ml or less or under 6.5 % 
of the serum concentration of GBG. When labeled CoF was added to serum 
below  the  binding  capacity,  complete complexation of the  CoF was  demon- 
strated,  whereas  CoF  was  largely  uncomplexed  when  CoF  was  added  in 
amounts equimolar to GBG. 436  RELATIONSHIP OF  ~-GLYCOPROTFIN TO  SERUM FACTORS 
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